Bart Vanhaesebroeck has made fundamental discoveries in the field of cell signalling by lipid second messengers, which have led to approved medicines.
Bart's contributions include uncovering the functions of PI 3-kinase (PI3K) family members and the identification of PI3Kdelta, expressed selectively in white blood cells. He has driven the generation of PI3Kdelta inhibitors that are currently used in cancer treatment and as immune therapeutics. His team’s development of PI3K activators has opened new avenues for kinase drug development and their therapeutic applications.
Bart studied Biology/Biochemistry at Ghent University in Belgium and received his PhD from the Laboratory of Molecular Biology with Walter Fiers in Ghent. He performed postdoctoral work with Mike Waterfield at the Ludwig Institute for Cancer Research in London, where he started his independent career.
Bart is an elected member of EMBO (European Molecular Biology Organization - 2008) and the UK Academy of Medical Sciences (2011). Bart is Professor of Cell Signalling at University College London.
Professional position
- Professor of Cell Signalling, Research Department of Oncology, University College London (UCL)
Subject groups
-
Molecules of Life
Biochemistry and molecular biology, Cell biology (incl molecular cell biology), Molecular immunology
-
Health and Human Sciences
Molecular medicine